Life Science Conference 2019

Price Forbes Event

EVENT DATE: 15 May 2019 - 17 May 2019

On Wednesday 15th – Friday 17th May, Price Forbes will be holding a Life Science Conference at the Macdonald Berystede Hotel and Spa in Ascot.

This conference is suitable for professionals working in the pharmaceutical industry looking to stay one step ahead of the political, legal and insurance landscape of life science and healthcare.

Guests will be welcomed with a three course dinner from 7pm on Wednesday 15th May. Throughout the event, guests can expect presentations on a range of topics. Click here for the full Agenda.

Key speakers include:

Buchanan Ingersoll & Rooney FDA group
Edward Allera is co-chair of Buchanan Ingersoll & Rooney FDA group. He counsels clients on new product development and business opportunities in the areas of pharmaceuticals, hi-tech products, medical devices, food and cosmetics. Ed has devoted his entire career to healthcare, as both a pharmacist and an attorney.

LYNNE BYERS Executive Director
NSF Health Sciences
Lynne Byers is an expert in pharmaceutical regulations, having worked as a regulator and in several multinational companies in global quality roles. She provides expert consultancy and training to clients.

Allenby Consulting
An independent consultant, Neil supports a number of Life Science companies in developing their insurance strategies, specialising in captives and structured reinsurance. He is also a core member of the team who developed EQuIP (non-damage BI insurance for LS companies). Formerly Risk Manager at AstraZeneca and Head of Life Sciences at JLT.

ERICA CONSTANCE Cyber Portfolio Manager
QBE European Operations
Erica leads the development and delivery of QBE’s strategy for Cyber across the European Operations, showcasing QBE’s solutions orientated approach. Erica’s remit includes ensuring that QBE’s proposition keeps pace with the rapidly evolving Cyber risk environment and that QBE remains relevant to customers and brokers.

ALEXANDER DAS Portfolio Manager Life Science Liability
QBE Insurance
Alex leads the underwriting strategy and performance of QBE European Operations’ UK and international Life Science liability book written from QBE’s London and overseas offices. His team develops and delivers flexible and relevant solutions to the exposures pertinent to the sector.

JANINA DIGGINS Senior Director
PAREXEL International
With 40 years’ experience in the insurance and financial services fields, Janina joined PAREXEL in 1999 and has been instrumental in designing and managing the company’s corporate insurance portfolio as well as developing many training programs and processes to support the company’s risk mitigation strategy, ensuring compliance with global insurance regulations. She has been recognised by clients and insurers as a leading expert in the arena of clinical trials insurance and has developed clinical trials insurance processes and training materials that have been adopted by clients and noted as best in class by regulatory authorities.

IAN DODDS-SMITH Head of European Product Liability
Arnold & Porter
Ian Dodds-Smith is head of Arnold & Porter’s European Product Liability practice and also co-head of the Food, Drug and Medical Device practice. Ian has primary responsibility for the European Union market. He advises companies and trade associations on all aspects of the regulatory framework within Europe.

Libbe Englander is the Founder and CEO of Pharm3r, a healthcare analytics company specialising in using real-world data for the post-market surveillance of drugs, devices, and manufacturing facilities. We partner with a growing client base of global product liability insurers as well as medical device and pharmaceutical companies. Prior to Pharm3r, Libbe founded, ran and successfully sold a long/short healthcare hedge fund.

LEE FARROW Executive Vice President
Lee oversees the strategy, operations, and underwriting of biotechnology, pharmaceutical, supplement and medical device companies, service companies, and human clinical trials. During 24 years in the insurance industry, Lee has had roles ranging from claims to in-house counsel to underwriting.

Intersys Ltd
Catherine advises biopharmaceutical companies on quantifying and managing supply chain risks. She has led the development of SCAIR®, a pharma-centric supply chain risk analysis tool and monitors disruption data and trends across the Life Science sector.

ADAM GROSSMAN Vice President, Modeling
Praedicat, Inc.
Adam Grossman, Ph.D., is the Vice President of Modelling and Senior Scientist at Praedicat. He develops Praedicat’s quantitative risk models for the insurance industry and leads Praedicat’s development of Life Science analytics and risk models.

Mishcon de Reya
Joe is the Head of Cyber at MDR Cyber. He focuses on providing strategic cyber advice, helping organisations to develop and optimise their investments in cyber risk management, and protect their reputation and stakeholders.

Arnold & Porter
Jeffrey is an experienced trial lawyer who has represented a wide range of clients in complex litigation and government investigations. His diverse practice includes major product liability, intellectual property and qui tam matters, as well as internal investigations, regulatory and compliance counseling and litigation avoidance counseling.

TINA KIRBY Head of Innovation and Product Development
Tina started as an underwriter in 1997 and has covered many lines of business including Terrorism, Contingency, Kidnap and Ransom, Political Risk, Product Recall, Liquidated Damages for construction projects, Intellectual Property loss or pursuit, Mergers & Acquisitions transition coverage and professional indemnity for lawyers, architects, contractors and engineers. In 2010 this diversity of experience led to her setting up and leading the Innovation and Product Development initiative with a global remit across all product lines.

PETRA MATES Underwriter
EQuIP Pharma Non-Damage BI at Munich Re
As member of the Life Science practice within Munich Re’s New Risk Solutions team, Petra provides bespoke cover for own and supplier sites of Pharma, Biopharma, Medical Device and CDMO companies.

LISA MITCHELL Senior Director, Global Risk Management
Syneos Health
Lisa Mitchell leads Risk Management at Syneos Health, a company that is purpose built to shorten the distance from lab to life. Her responsibilities include developing and leading the Enterprise Risk Management program and global business insurances. Her career has spanned global manufacturing and professional services across information technology and risk management through both the financial and legal lens.

LINDA SCHULTZ Head of Life Science
Navigators Health, Science & Technology Practice
Linda has responsibility for the practice’s product liability insurance underwriting and coverage provisions for biotech, pharmaceuticals, medical device manufacturers and R&D providers. Her team evaluates product liability exposures and risk management practices of customers ranging from start-ups to global corporations.

CHRIS TERRY Underwriter
Allianz Global Corporate & Specialty
Chris is an underwriter within the ART LoB of Allianz Global Corporate & Specialty, the division of Allianz which focuses on large global corporates. Chris helps companies build innovative tailor-made (re)insurance programs designed to optimise the balance between risk retention and risk transfer typically on a multi-year and multi-line basis.

PETER TILLMANS Head of Liability Underwriting Specialities and Head of Financial Lines Underwriting
HDI Global SE
Peter has responsibility for large Pharma, Hospitals as well as other business and 30 years of Liability Underwriting know-how.

KERRY WEEMS Chief Executive Officer
Mycroft Bioanalytics
Chief Executive Officer of Mycroft Bioanalytics and Executive Chairman of the value-based HealthCare Investors Alliance. He works with clients and members to promote and implement value-based reimbursement and pricing for pharmaceuticals, devices, insurance, and health services.

JENNY YU Senior Underwriter for Life Sciences Industry
Munich Re
Jenny Yu is a Senior Underwriter at Munich Re and heads up a Life Science team specialising in providing bespoke and new risk solutions for the Pharma, Biotech and Medical Device companies. She has provided solutions for small, medium and large companies in North America and Europe.

The event will conclude at 12.30pm on Friday 17th May and is set to be a key date in the calendar of: insurers, brokers and risk/insurance managers working within the pharmaceutical industry.

Share this:

Other Events

See More Events